JB Financial chief buys W200m in treasury shares
Kim Ki-hong, chair and CEO of JB Financial Group, has purchased an additional 200 million won ($141,000) worth of treasury shares as part of ongoing efforts to enhance corporate value and shareholder returns.
According to a recent regulatory filing with the Financial Supervisory Service, Kim acquired 12,127 shares on the open market on April 9 at 16,542 won per share.
The latest purchase raises Kim's total holdings to 160,000 shares, equivalent to 0.08 percent of JB Financial Group's outstanding shares. That places him among the largest individual shareholders across the chairs of South Korea's seven major financial holding groups.
Headquartered in North Jeolla Province, JB Financial is a regional banking group that trails Seoul-based giants such as KB, Shinhan and Hana in size and market presence. Kim's continued share purchases stand out against that backdrop, underscoring a leadership strategy centered on shareholder alignment and long-term value creation.
Since taking the helm in 2019, Kim has bought treasury shares on seven occasions, reinforcing his commitment to bolstering market confidence in the group. During the period, JB Financial's stock value surged nearly 180 percent.
Kim was recently reappointed in March for a third term, extending his tenure by another three years.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
4 hours ago
- Korea Herald
S. Korea-China-Japan cooperation crucial as ‘buffer' as Trump 2.0 roils Asia
APEC summit will serve as springboard for bolstering trilateral coordination, observers say Trilateral cooperation among South Korea, China and Japan has become more essential than ever as a buffer in Northeast Asia fraught with mounting volatility and uncertainty under US President Trump's second term, former high-ranking officials and experts said. Observers from the three countries held the view that Northeast Asia has become the central battleground in the intensifying great-power rivalry between the US and China during a forum hosted by the North-East Asia Research Foundation, a Seoul-based think tank, on Monday. Chung Duck-koo, former minister of trade, industry and energy, underscored that 'further strengthening trilateral relations among South Korea, China and Japan would be highly beneficial,' as Northeast Asia sits at the fault line between the North Korea–China–Russia bloc and South Korea–US–Japan cooperation. 'As a group that intersects both triangular frameworks, our cooperation could serve as a bridge for promoting shared prosperity and safety,' Chung, who serves as the founder and incumbent chair of the NEAR Foundation, said in his opening speech during the forum "The Trump 2.0 Era and its Implications on Northeast Asia." "Such efforts could help ease or neutralize tensions and mitigate sources of conflict in the region." Kim Sung-han, a former national security adviser in the previous Yoon Suk Yeol administration, underscored that "the geopolitical confrontation between North Korea–China–Russia alignment and the ROK–US–Japan partnership is likely to intensify further." The ROK stands for the Republic of Korea, the official name of South Korea. Kim elucidated that the US has been doubling down on its strategic pivot to the Indo-Pacific region from Europe, setting the termination of the war in Ukraine in sight, while curtailing its military engagement in the Middle East. At the same time, China is expected to bolster its strategic partnership with Russia while reinvigorating ties with North Korea. 'In this context, trilateral cooperation among ROK, China and Japan becomes increasingly important to help ease regional tensions and prevent further polarization,' commented Kim, who currently serves as a professor of the Graduate School of International Studies at Korea University. Kim further explained, 'Trump 2.0's foreign policy is likely to push the Northeast Asian order toward a binary confrontation, which could weaken the strategic foundation for trilateral cooperation among ROK, China and Japan." 'Paradoxically, however, in the face of rising tensions, pragmatic and interest-based cooperation among those three countries may become even more necessary,' Kim said. 'As a result, Korea-China-Japan trilateral cooperation could serve as a 'diplomatic shock absorber' that helps ease geopolitical tensions and maintain regional equilibrium.' In his keynote address, Yun Byung-se, former foreign minister under the Park Geun-hye administration, said, 'Dialogue, exchanges and cooperation among South Korea, China and Japan are extremely valuable assets, amid the seismic geopolitical and geoeconomic shifts.' Observers also concurred that the North Korean nuclear challenge underscored the need for tighter Korea-China-Japan cooperation. Yun pointed out that 'North Korea will negotiate from its most advantageous strategic position since the Korean War' if a summit between Trump and North Korean leader Kim Jong-un materializes. 'Depending on the result, another shock may come to the landscape of Northeast Asia,' Yun said. 'Prior coordination between South Korea and the US, and among South Korea, the US and Japan, as well as close consultation with China, will be necessary.' Voicing similar views, Hitoshi Tanaka, former deputy foreign minister in Japan, also underscored that 'especially on pressing issues such as North Korea's nuclear program, close trilateral coordination is imperative.' Observers said this year's Asia-Pacific Economic Cooperation summit — set for late October to early November in Gyeongju, North Gyeongsang Province — will provide a valuable venue to advance trilateral cooperation. 'We understand China's sensitivity regarding Taiwan,' Tanaka said. 'However, just as APEC clearly separates political and security matters, including Taiwan in such frameworks should be considered to demonstrate that economic cooperation can transcend political divides.' The APEC summit will invite leaders from 21 countries in the Indo-Pacific region, including South Korea, the US, China, Japan and Taiwan. 'We hope that the leaders of our three countries — South Korea, China and Japan — will also take advantage of this opportunity to engage in meaningful dialogue,' Chung of the NEAR Foundation said. 'Regardless of the challenges that may arise, South Korea, China and Japan should aim to be in the same boat and remain committed to discussing any issue in depth. In this regard, we must not make the mistake of allowing the past to hinder the future,' Chung added.
Korea Herald
4 hours ago
- Korea Herald
Samsung Bioepis partners with Nipro for Japan market entry
Samsung Bioepis, the biosimilar unit of Samsung Group, announced Monday that it has signed a commercialization agreement with Japan-based pharmaceutical and medical device company Nipro to enter the Japanese market. The deal covers the licensing, development and commercialization of multiple biosimilars, including SB17, a biosimilar referencing Stelara (ustekinumab), used to treat autoimmune conditions. This marks the company's first partnership with a Japanese pharmaceutical company. Under the agreement, Samsung Bioepis will oversee development, manufacturing and supply, while Nipro will manage sales and distribution in Japan. 'The partnership is a major milestone for our entry into Japan,' said Samsung Bioepis CEO Kim Kyung-ah. 'We aim to enhance patient access to high-quality biopharmaceuticals through close collaboration with local partners.' SB17 is a biosimilar to Janssen's Stelara, which treats inflammatory diseases such as psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis. Samsung Bioepis launched its proprietary Stelara biosimilar, Pyzchiva, in the US earlier this year, followed by an increased market competition after Stelara's US patent expiry in 2023. After receiving approval in Europe last year, Pyzchiva went on to secure a 43 percent market share, emerging as a leading product in the region's biosimilar market. Founded in 2012, Samsung Bioepis has gained approval for 11 blockbuster biosimilar products and posted 1.54 trillion won ($1.13 billion) in revenue in 2024. Meanwhile, Samsung Bioepis is scheduled to separate from its parent company, Samsung Biologics, in October to operate as a new holding company, a strategic move aimed at easing client concerns over potential conflicts of interest between Samsung Biologics' contract development and manufacturing business and Samsung Bioepis' biosimilar unit.
Korea Herald
2 days ago
- Korea Herald
HIRONIC Successfully Hosts First Asia Innovation Summit 2025
SEOUL, South Korea, June 7, 2025 /PRNewswire/ -- HIRONIC, a global leader in non-invasive medical aesthetic technology, has successfully hosted its inaugural 'HIRONIC Innovation Summit 2025. Asia Edition' in Bangkok, Thailand on June 5th. The event brought together approximately 100 medical professionals and medical distribution industry representatives from South Korea, Thailand, Vietnam, Malaysia, Indonesia, Myanmar, and other countries. Across four in-depth clinical sessions, speakers presented the latest approaches to skin rejuvenation, covering multi-layered face and body lifting, advanced scar treatment, and next-generation needle-free drug delivery technologies. One of the keynote lectures was delivered by Dr. Wonkyu Hong, Director and dermatologist at Human Dermatology Clinic and Executive Director of the Human Clinical Trial Center in South Korea. Dr. Hong explored the rapidly evolving role of needle-free technology in aesthetic medicine, sharing his clinical experience while emphasizing both its therapeutic advantages and its significant market growth potential driven by increasing patient demand for non-invasive rejuvenation solutions. Dr. Thitikom Limrattanamekha, founder and CEO of Optima Aesthetics in Thailand and an experienced laser specialist in scar treatment, skin quality improvement, and pigmentation management, shared his expertise on combining pico laser and RF microneedling to achieve highly effective outcomes in complex scarring cases. His presentation highlighted how advanced combination protocols are reshaping non-surgical treatment approaches and expanding therapeutic options for physicians worldwide. The symposium also provided a platform to showcase the clinical advancements and growing market relevance of HIRONIC's flagship export technologies, including New Doublo™, PICOHI™, and the latest needle-free delivery system Synerjet PRO™. Sasha Borovtsova, Head of Global Marketing Office at HIRONIC, stated, "This summit not only showcased the real-world clinical applications of our technologies but also underscored the accelerating global demand for safer, more versatile, and highly effective aesthetic solutions. As innovation continues to drive market growth, HIRONIC remains committed to advancing technology and strengthening global expertise and partnerships through events like the HIRONIC Innovation Summit." Headquartered in South Korea, HIRONIC is a leading global manufacturer of medical aesthetic devices, specializing in HIFU, RF, laser, and needle-free technologies. With a presence in over 80 countries, HIRONIC has introduced iconic devices such as Doublo™, Doublo Gold™, and New Doublo 2.0™ to the international market.
